TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

Rory M. Shallis; Naval G. Daver; Jessica K. Altman; Robert P. Hasserjian; Hagop M. Kantarjian; Uwe Platzbecker; Valeria Santini; Andrew H. Wei; David A. Sallman; Amer M. Zeidan

doi:10.1002/cncr.34535

TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

Rory M. Shallis
, Naval G. Daver
, Jessica K. Altman
, Robert P. Hasserjian
, Hagop M. Kantarjian
, Uwe Platzbecker
, Valeria Santini
, Andrew H. Wei
, David A. Sallman
, Amer M. Zeidan

Leukemia

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.

Original language	English (US)
Pages (from-to)	175-180
Number of pages	6
Journal	Cancer
Volume	129
Issue number	2
DOIs	https://doi.org/10.1002/cncr.34535
State	Published - Jan 15 2023

Keywords

acute myeloid leukemia (AML)
cutoff
excess blasts
myelodysplastic syndrome (MDS)
p53
TP53

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cncr.34535

Cite this

@article{10ad651ea1a843b593d0e0cdb717a45d,

title = "TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity",

abstract = "TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.",

keywords = "acute myeloid leukemia (AML), cutoff, excess blasts, myelodysplastic syndrome (MDS), p53, TP53",

author = "Shallis, \{Rory M.\} and Daver, \{Naval G.\} and Altman, \{Jessica K.\} and Hasserjian, \{Robert P.\} and Kantarjian, \{Hagop M.\} and Uwe Platzbecker and Valeria Santini and Wei, \{Andrew H.\} and Sallman, \{David A.\} and Zeidan, \{Amer M.\}",

note = "Publisher Copyright: {\textcopyright} 2022 American Cancer Society.",

year = "2023",

month = jan,

day = "15",

doi = "10.1002/cncr.34535",

language = "English (US)",

volume = "129",

pages = "175--180",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

AU - Shallis, Rory M.

AU - Daver, Naval G.

AU - Altman, Jessica K.

AU - Hasserjian, Robert P.

AU - Kantarjian, Hagop M.

AU - Platzbecker, Uwe

AU - Santini, Valeria

AU - Wei, Andrew H.

AU - Sallman, David A.

AU - Zeidan, Amer M.

PY - 2023/1/15

Y1 - 2023/1/15

N2 - TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.

AB - TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.

KW - acute myeloid leukemia (AML)

KW - cutoff

KW - excess blasts

KW - myelodysplastic syndrome (MDS)

KW - p53

KW - TP53

UR - https://www.scopus.com/pages/publications/85142256034

UR - https://www.scopus.com/pages/publications/85142256034#tab=citedBy

U2 - 10.1002/cncr.34535

DO - 10.1002/cncr.34535

M3 - Article

C2 - 36397669

AN - SCOPUS:85142256034

SN - 0008-543X

VL - 129

SP - 175

EP - 180

JO - Cancer

JF - Cancer

IS - 2

ER -

TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this